Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| ORBOTECH LTD | ORBK | 10.86% |
| SONIC FOUNDR | SOFO | 9.45% |
| VIPSHOP HOLD | VIPS | 9.20% |
| RENEWABLE EN | REGI | 8.98% |
| EAGLE BULK S | EGLE | 7.84% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Recently, Neogen Corporation ( NEOG - Snapshot Report ) acquired Fort Collins, Colorado-based Macleod Pharmaceuticals. Following the acquisition, the privately-owned Macleod business will be a part of Neogen’s animal safety group.
Macleod, an animal health company, is the original manufacturer of Uniprim, the popular antibiotic drug for horses. The antibiotic is widely distributed across the U.S. Macleod’s exclusive distribution agreement with Bio-Agri Mix has made it possible for Uniprim to be easily available in Canada. The change in ownership will not affect Macleod’s current employees as Neogen plans to retain staff and continue to operate from the Fort Collins facility.
The acquisition is in line with Neogen’s strategy of acquiring allied businesses and developing key alliances. Uniprim will enhance Neogen’s portfolio of professional equine products. It also presents a significant commercial opportunity and is expected to garner incremental revenues for animal safety segment. Revenues from the animal safety segment (43.7% of total revenues) increased 5% year over year to $23.5 million in the first quarter of fiscal 2013.
Neogen has been assiduously expanding its animal safety segment through acquisitions. The company acquired GeneSeek in 2010 to add depth and dynamism to its animal safety segment. In 2012, Neogen acquired Igenity animal genomics business from Merial Limited.
Macleod’s revenues for the last twelve months were roughly $4 million. Neogen witnessed year-over-year revenue growth of 8.8% to $49.7 million in the most recent quarter. Excluding contributions from the Igenity animal genomics business, the company’s revenues edged up 8.1% year over year.
Neogen is a provider of food and animal safety products. The company’s acquisition strategy, sales and marketing capabilities for specific markets and international operations continue to boost its top-line. However, competition from IDEXX Laboratories ( IDXX - Snapshot Report ) in certain niche areas remains a headwind.
Neogen currently has a Zacks #3 Rank, which translates into a short-term Hold rating.
Read the full Snapshot Report on IDXX
Read the full Snapshot Report on NEOG